First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney.OPTIMAL-e will evaluate TLX597-Tx in earlier ...

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof.Patient care and research delivered in collaboration with the ...

The Defense Secretary said the push to provide this care was not about artificial enhancements. “It’s about restoring and ...

In a new research report, scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center ...

Prostate cancer is often resistant to immunotherapy, which harnesses a person's immune system to recognize and destroy tumors ...

Joe Biden has shared a personal health update while announcing his upcoming memoir. The former president said his cancer ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be ...

Russ Reed finally got his cancer drug, but others mired in red tape. “There are a lot of people who are going to die ...

QUINCY — Men experiencing erectile dysfunction, Peyronie’s disease, or bladder leakage following prostate cancer treatment are invited to attend a free educational webinar hosted by Blessing Health ...

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its ...

Ryan Kohlbrenner, MD, interventional radiologist at the UCSF Department of Radiology & Biomedical Imaging, is leading a new ...

Immunotherapy: Hope, Hurdles, and a Clever Disguise Immunotherapies stand as one of the most promising paths in modern cancer treatment. Their main goal? To help the body’s own immune system hunt down ...